Vorapaxar information

Vorapaxar
Clinical data
Trade names	Zontivity
Other names	SCH-530348
Routes of; administration	By mouth
ATC code	B01AC26 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Bioavailability	~100%
Protein binding	≥99%
Metabolism	hepatic (CYP3A4 and CYP2J2)
Elimination half-life	5–13 days
Excretion	feces (58%), urine (25%)
Identifiers
	IUPAC name Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate;
CAS Number	618385-01-6 ;
PubChem CID	10077130;
IUPHAR/BPS	4047;
ChemSpider	8252668 ;
UNII	ZCE93644N2;
ChEBI	CHEBI:82702 ;
ChEMBL	ChEMBL493982 ;
CompTox Dashboard (EPA)	DTXSID201009336 ;
ECHA InfoCard	100.116.767
Chemical and physical data
Formula	C29H33FN2O4
Molar mass	492.591 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	278 °C (532 °F)
	SMILES Fc1cccc(c1)c2ccc(nc2)\C=C\[C@H]4[C@H]3[C@@H](C[C@H](NC(=O)OCC)CC3)C[C@H]5C(=O)O[C@@H]([C@@H]45)C;
	InChI InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1 ; Key:ZBGXUVOIWDMMJE-QHNZEKIYSA-N ;
	(what is this?) (verify)

Vorapaxar (brand name Zontivity, formerly known as SCH 530348) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.^[3]

^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ "ZONTIVITY™ (vorapaxar) Tablets 2.08 mg, for oral use. Full Prescribing Information" (PDF). Merck & Co., Inc. Initial U.S. Approval: 05/2014. Retrieved 17 June 2014.
^ Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, et al. (June 2008). "Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity". Journal of Medicinal Chemistry. 51 (11): 3061–3064. doi:10.1021/jm800180e. PMID 18447380.

[1] "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

[zontivity-2] "ZONTIVITY™ (vorapaxar) Tablets 2.08 mg, for oral use. Full Prescribing Information" (PDF). Merck & Co., Inc. Initial U.S. Approval: 05/2014. Retrieved 17 June 2014.

[pmid18447380-3] Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, et al. (June 2008). "Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity". Journal of Medicinal Chemistry. 51 (11): 3061–3064. doi:10.1021/jm800180e. PMID 18447380.

Vorapaxar information

and 4 Related for: Vorapaxar information

Vorapaxar

Himbacine

Antiplatelet drug

ATC code B01